INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19
12/08/2020

INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19

PLYMOUTH MEETING, Pa., Dec. 7, 2020 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechno...
read more